Targets › RAF1
11 programs from 10 companies in 81 trials: 53 Phase 2, 21 Phase 1, 7 Phase 3; Oncology; next expected readout Nov 2026.
Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential…. (UniProt, P04049)
Open in Phaseline: the race on RAF1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Erasca | Naporafenib B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor | RAF1, BRAF | Phase 3 | Advanced or Metastatic NRAS-mutant Melanoma; Advanced or Metastatic Solid Tumors | Dec 2026 |
| Day One Biopharmaceuticals | Tovorafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 3 | Low-grade Glioma; Craniopharyngioma, Child; Recurrent Langerhans Cell Histiocytosis; Hairy Cell Leukemia | May 2027 |
| Roche | Sorafenib Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | RAF1, PDGFRB, KIT, FLT3, BRAF | Phase 3 | Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma … | – |
| The First Affiliated Hospital with Nanjing Medical University | Donafenib RAF kinase inhibitor | RAF1 | Phase 2 | Biliary Malignant Tumors | Nov 2026 |
| Novartis | Naporafenib (LXH254) B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor | RAF1, BRAF | Phase 2 | Melanoma; EGFR-mutant Non-small Cell Lung Cancer | Feb 2027 |
| National Cancer Institute (NCI) | Sorafenib Tosylate Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | RAF1, PDGFRB, KIT, FLT3, BRAF | Phase 2 | Gastrointestinal Stromal Tumor; Acute Myeloid Leukemia; Advanced Malignant Solid Neoplasm | Mar 2027 |
| Bayer | Regorafenib (BAY73) Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor | ABL1, RAF1, KIT, FGFR1, MAPK11 | Phase 2 | Solid Malignant Tumors; Metastatic Colorectal Cancer (mCRC); Colorectal Cancer Liver Metastases; Colorectal Cancer Metastatic … | Apr 2028 |
| Hanmi Pharmaceutical Company | Belvarafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 2 | Advanced or Metastatic Melanoma | Sep 2029 |
| Roche | Belvarafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 1 | Melanoma; Primary Brain Tumor | Dec 2026 |
| Nested Therapeutics | NST-628 non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway | RAF1, MAP2K1 | Phase 1 | Oncology | Nov 2028 |
| Ipsen | Tovorafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 1 | Low-grade Glioma | Jul 2030 |
Hepatocellular Carcinoma (7) Low-grade Glioma (3) Colorectal Cancer Metastatic (2) Melanoma Stage III (2) Unresectable Hepatocellular Carcinoma (2) Gastrointestinal Stromal Tumors (2) Ovarian Cancer (2) Colorectal Cancer (2) Metastatic Colorectal Cancer (2) Hepato Cellular Carcinoma (HCC) (2) Melanoma (2) Neuroblastoma (2)
small molecule (9), mixed (2)
Roche (2) The First Affiliated Hospital with Nanjing Medical University (1) Erasca (1) National Cancer Institute (NCI) (1) Bayer (1) Day One Biopharmaceuticals (1) Nested Therapeutics (1) Ipsen (1) Novartis (1) Hanmi Pharmaceutical Company (1)
BRAF (8) ARAF (4) KIT (3) PDGFRB (2) FLT3 (2) ABL1 (1) FGFR1 (1) MAPK11 (1) MAP2K1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.